E. Outcome-trial, In this trial, empagliflozin reduced the risk of a broad spectrum of HF outcomes with no heterogeneity observed among patients with or without HF at baseline, vol.75

, J. Clin. Med, vol.2020

B. A. Borlaug and W. J. Paulus, Heart failure with preserved ejection fraction: Pathophysiology, diagnosis and treatment, Eur. Heart J, vol.32, pp.670-679, 2011.

R. Ferrari, M. Bohm, J. G. Cleland, W. J. Paulus, B. Pieske et al., Heart failure with preserved ejection fraction: Uncertainties and dilemmas, Eur. J. Heart Fail, vol.17, pp.665-671, 2015.

, J. Clin. Med, vol.2020, p.1110

K. Sharma and D. A. Kass, Heart failure with preserved ejection fraction: Mechanisms, clinical features, and therapies, Circ. Res, vol.115, pp.79-96, 2014.

D. S. Lee, P. Gona, R. S. Vasan, M. G. Larson, E. J. Benjamin et al., Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute, Circulation, vol.119, pp.3070-3077, 2009.

R. S. Bhatia, J. V. Tu, D. S. Lee, P. C. Austin, J. Fang et al., Outcome of heart failure with preserved ejection fraction in a population-based study, N. Eng. J. Med, vol.355, pp.260-269, 2006.

S. Yusuf, M. A. Pfeffer, K. Swedberg, C. B. Granger, P. Held et al., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial, Lancet, vol.362, pp.777-781, 2003.

B. M. Massie, P. E. Carson, J. J. Mcmurray, M. Komajda, R. Mckelvie et al., Irbesartan in patients with heart failure and preserved ejection fraction, N. Engl. J. Med, vol.359, pp.2456-2467, 2008.

J. G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski et al., The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur. Heart J, vol.27, pp.2338-2345, 2006.

D. W. Kitzman, W. G. Hundley, P. H. Brubaker, T. M. Morgan, J. B. Moore et al., A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: Effects on exercise tolerance and arterial distensibility, Circ. Heart Fail, vol.3, pp.477-485, 2010.

B. Pitt, M. A. Pfeffer, S. F. Assmann, R. Boineau, I. S. Anand et al., Spironolactone for heart failure with preserved ejection fraction, N. Engl. J. Med, vol.370, pp.1383-1392, 2014.

A. Ahmed, M. W. Rich, J. L. Fleg, M. R. Zile, J. B. Young et al., Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial, Circulation, vol.114, pp.397-403, 2006.

G. W. Yip, M. Wang, T. Wang, S. Chan, J. W. Fung et al., The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction, vol.94, pp.573-580, 2008.

M. M. Redfield, H. H. Chen, B. A. Borlaug, M. J. Semigran, K. L. Lee et al., Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial, JAMA, vol.309, pp.1268-1277, 2013.

R. Samson, A. Jaiswal, P. V. Ennezat, M. Cassidy, and T. H. Le-jemtel, Clinical Phenotypes in Heart Failure with Preserved Ejection Fraction, J. Am. Heart Assoc, 2016.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. G. Cleland et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur. Heart J, vol.37, pp.2129-2200, 2016.

M. R. Zile, W. H. Gaasch, J. D. Carroll, M. D. Feldman, G. P. Aurigemma et al., Heart failure with a normal ejection fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation, vol.104, pp.779-782, 2001.

P. V. Ennezat, T. J. Le, D. Logeart, and S. Maréchaux, Heart failure with preserved ejection fraction: A systemic disorder?, Rev. Med. Interne, vol.33, pp.370-380, 2012.

W. J. Paulus, Unfolding Discoveries in Heart Failure, N. Engl. J. Med, vol.2020, pp.679-682

A. Bayes-genis, D. Pascual-figal, and J. Núñez, The pre-HFpEF stage: A new entity that requires proper phenotyping for better management, Eur. J. Prev. Cardiol, 2020.

C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey et al., ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol, vol.62, pp.147-239, 2013.

, J. Clin. Med, vol.2020, p.1110

F. Bisbal, A. Baranchuk, E. Braunwald, A. Bayés-de-luna, and A. Bayés-genís, Atrial failure as a clinical entity: JACC review topic of the week, J. Am. Coll. Cardiol, vol.2020, pp.222-232

A. B. Santos, E. Kraigher-krainer, D. K. Gupta, B. Claggett, M. R. Zile et al., Impaired left atrial function in heart failure with preserved ejection fraction, Eur. J. Heart Fail, vol.16, pp.1096-1103, 2014.

M. Habibi, H. Chahal, A. Opdahl, O. Gjesdal, T. M. Helle-valle et al., Association of CMR-measured LA function with heart failure development: Results from the MESA study, JACC Cardiovasc. Imaging, vol.7, pp.570-579, 2014.

U. Sartipy, U. Dahlström, M. Fu, and L. H. Lund, Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction, JACC Heart Fail, vol.5, pp.565-574, 2017.

V. Melenovsky, S. J. Hwang, M. M. Redfield, R. Zakeri, G. Lin et al., Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction, Circ. Heart Fail, vol.8, pp.295-303, 2015.

Y. T. Tan, F. Wenzelburger, E. Lee, P. Nightingale, G. Heatlie et al., Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction, vol.96, pp.1017-1023, 2010.

V. Roeder, M. Rommel, K. P. Kowallick, J. T. Blazek, S. Besler et al., Influence of left atrial function on exercise capacity and left ventricular function in patients with heart failure and preserved ejection fraction, Circ. Cardiovasc. Imaging, vol.10, 2017.

F. Telles, S. Nanayakkara, S. Evans, H. C. Patel, J. A. Mariani et al., Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction, Eur. J. Heart Fail, vol.21, pp.495-505, 2019.

L. Sanchis, L. Gabrielli, R. Andrea, C. Falces, N. Duchateau et al., Left atrial dysfunction relates to symptom onset in patients with heart failure and preserved left ventricular ejection fraction, Eur. Heart J. Cardiovasc. Imaging, vol.16, pp.62-67, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02282410

J. T. Kühl, J. E. Møller, T. S. Kristensen, H. Kelbaek, and K. F. Kofoed, Left atrial function and mortality in patients with NSTEMI an MDCT study, JACC Cardiovasc. Imaging, vol.4, pp.1080-1087, 2011.

K. Negishi, T. Negishi, O. Zardkoohi, E. A. Ching, N. Basu et al., Left atrial booster pump function is an independent predictor of subsequent life-threatening ventricular arrhythmias in non-ischaemic cardiomyopathy, Eur. Heart J. Cardiovasc. Imaging, vol.17, pp.1153-1160, 2016.

A. B. Santos, G. Q. Roca, B. Claggett, N. K. Sweitzer, S. J. Shah et al., Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction, Circ. Heart Fail, vol.9, 2016.

J. C. Eicher, G. Laurent, A. Mathé, O. Barthez, G. Bertaux et al., Atrial dyssynchrony syndrome: An overlooked phenomenon and a potential cause of "diastolic" heart failure, Eur. J. Heart Fail, vol.14, pp.248-258, 2012.

G. Laurent, J. C. Eicher, A. Mathe, G. Bertaux, O. Barthez et al., Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: A pilot study prior to a national clinical research programme, Eur. J. Heart Fail, vol.15, pp.85-93, 2013.

B. Zafrir, L. H. Lund, C. Laroche, F. Ruschitzka, M. G. Crespo-leiro et al., Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: A report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry, Eur. Heart J, vol.39, pp.4277-4284, 2018.

M. Packer, C. S. Lam, L. H. Lund, and M. M. Redfield, Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy, Circulation, vol.141, pp.4-6, 2020.

M. Tamargo, M. Obokata, Y. N. Reddy, S. V. Pislaru, G. Lin et al., Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction, Eur. J. Heart Fail, 2020.

, J. Clin. Med, vol.2020, p.1110

M. Obokata, Y. N. Reddy, and B. A. Borlaug, Diastolic dysfunction and heart failure with preserved ejection fraction, J. Am. Coll. Cardiol. Imaging, vol.12, pp.2098-2099, 2019.

C. S. Lam, A. A. Voors, R. A. De-boer, S. D. Solomon, and D. J. Van-veldhuisen, Heart failure with preserved ejection fraction: From mechanisms to therapies, Eur. Heart J, vol.39, pp.2780-2792, 2018.

G. A. Lewis, E. B. Schelbert, S. G. Williams, C. Cunnington, F. Ahmed et al., Biological phenotypes of heart failure with preserved ejection fraction, J. Am. Coll. Cardiol, vol.70, pp.2186-2200, 2017.

T. M. Gorter, E. S. Hoendermis, D. J. Van-veldhuisen, A. A. Voors, C. S. Lam et al., Right ventricular dysfunction in heart failure with preserved ejection fraction: A systematic review and meta-analysis, Eur. J. Heart Fail, vol.18, pp.1472-1487, 2016.

T. M. Gorter, D. J. Van-veldhuisen, J. Bauersachs, B. A. Borlaug, J. Celutkiene et al., Right heart dysfunction and failure in heart failure with preserved ejection fraction: Mechanisms and management. Position Statement on behalf of the Heart Failure Association of the European Society of Cardiology, Eur. J. Heart Fail, vol.20, pp.16-37, 2018.

M. Obokata, G. C. Kane, Y. N. Reddy, V. Melenovsky, T. P. Olson et al., The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.3707-3717, 2019.

A. U. Fayyaz, W. D. Edwards, J. J. Maleszewski, E. A. Konik, H. M. Dubrock et al., Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction, Circulation, vol.137, pp.1796-1810, 2018.

T. P. Olson, B. D. Johnson, and B. A. Borlaug, Impaired pulmonary diffusion in heart failure with preserved ejection fraction, JACC Heart Fail, vol.4, pp.490-498, 2016.

M. M. Hoeper, K. Meyer, J. Rademacher, J. Fuge, T. Welte et al., Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction, JACC Heart Fail, vol.4, pp.490-498, 2016.

L. Du, C. C. Sullivan, D. Chu, A. J. Cho, M. Kido et al., Signaling molecules in nonfamiliar pulmonary hypertension, N. Eng. J. Med, vol.348, pp.500-509, 2003.

M. M. Hoeper, C. S. Lam, J. L. Vachiery, J. Bauersachs, C. Gerges et al., Pulmonary hypertension in heart failure with preserved ejection fraction: A plea for proper phenotyping and further research, Eur. Heart J, vol.38, pp.2869-2873, 2017.

N. Galiè, M. Humbert, J. L. Vachiery, S. Gibbs, I. Lang et al., ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the, Endorsed by Association for European Pediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Trasplantation (ISHLT), vol.37, pp.67-119, 2015.

T. M. Gorter, D. J. Van-veldhuisen, A. A. Voors, Y. M. Hummel, C. S. Lam et al., Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre-vs. post-capillary pulmonary hypertension, Eur. J. Cardiovasc. Imaging, vol.19, pp.425-432, 2018.

M. Gerges, C. Gerges, A. M. Pistritto, M. B. Lang, P. Trip et al., Pulmonary hypertension in heart failure. Epidemiology, right ventricular function and survival, Am. J. Respir Crit. Care Med, vol.192, pp.1234-1246, 2015.

M. Guazzi, D. Dixon, V. Labate, L. Beussink-nelson, F. Bandera et al., RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction. Stratification of clinical phenotypes and outcomes, J. Am. Coll. Cardiol. Imaging, vol.10, pp.1211-1221, 2017.

E. Santas, P. Palau, M. Guazzi, R. De-la-espriella, G. Miñana et al., Uselfulness of right ventricular to pulmonary circulation coupling as an indicator of risk for recurrent admissions in heart failure with preserved ejection fraction, Am. J. Cardiol, vol.124, pp.567-572, 2019.

E. Santas, F. J. Chorro, G. Miñana, J. Méndez, J. Muñoz et al., Tricuspid regurgitation and mortality risk across left ventricular systolic function in acute heart failure, Circ. J, vol.79, pp.1526-1533, 2015.

R. De-la-espriella, E. Santas, F. J. Chorro, G. Miñana, M. Soler et al., Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure, Int. J. Cardiol, vol.291, pp.83-88, 2019.

M. Taramaso, M. Gavazzoni, and F. Maisano, Is tricuspid regurgitation a prognostic intervetional target or is it just an indicator of worst prognosis in heart failure patients?, Eur. Heart J, vol.40, pp.485-487, 2019.

S. Rosenkranz, L. S. Howard, M. Gomberg-maitland, and M. M. Hoeper, Systemic consequences of pulmonary hypertension and right-sided heart failure, Circulation, vol.141, pp.678-693, 2020.

B. A. Borlaug and M. Obokata, Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease, Eur. Heart J, vol.38, pp.2874-2878, 2017.

S. Aschauer, C. Zotter-tufaro, F. Duca, A. Kammerlander, and D. Dalos, Modes of death in patients with heart failure and preserved ejection fraction, Int. J. Cardiol, vol.228, pp.422-426, 2017.

B. A. Borlaug, G. C. Kane, V. Melenovsky, and T. P. Olson, Abnormal right ventricular-pulmonary artery coupling in exercise in heart failure with preserved ejection fraction, Eur. Heart J, vol.37, pp.3293-3302, 2016.

K. Nochioka, G. Q. Roca, B. Claggett, T. Biering-sørensen, K. Matsushita et al., Right ventricular function, right ventricular-pulmonary artery coupling, and heart failure risk 4 US communities. The Atherosclerosis Risk in Communities (ARIC) Study, JAMA Cardiol, vol.3, pp.939-948, 2018.

Y. N. Reddy, M. Obokata, B. Wiley, K. E. Koepp, C. C. Jorgenson et al., The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.3721-3730, 2019.

M. Obokata, Y. N. Reddy, V. Melenovsky, S. Pislaru, and B. A. Borlaug, Deterioration in right ventricular structure and function over time in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.689-697, 2019.

T. M. Gorter, D. J. Van-veldhuisen, and A. A. Voors, Rapid right-sided deterioration in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.699-702, 2019.

L. Xhakollari, M. Leosdottir, M. Magnusson, M. J. Holzmann, P. M. Nilsson et al., Echocardiographic Findings in Patients with Mild to Moderate Chronic Kidney Disease without Symptomatic Heart Failure: A Population-Based Study, Cardiorenal Med, vol.9, pp.284-296, 2019.

B. Afsar, P. Rossignol, L. Van-heerebeek, W. J. Paulus, K. Damman et al., Heart failure with preserved ejection fraction: A nephrologist-directed primer, Heart Fail. Rev, vol.22, pp.765-773, 2017.

F. Zannad, P. Rossignol, W. G. Stough, M. Epstein, M. D. Garcia et al., New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval, Int. J. Cardiol, vol.216, pp.46-51, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01760299

P. Rossignol, A. F. Hernandez, S. D. Solomon, and F. Zannad, Heart failure drug treatment, Lancet, vol.393, pp.1034-1044, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02510811

F. Zannad and P. Rossignol, Cardiorenal Syndrome Revisited. Circulation, vol.138, pp.929-944, 2018.

C. Zoccali, R. Vanholder, Z. A. Massy, A. Ortiz, P. Sarafidis et al., The systemic nature of CKD, Nat. Rev. Nephrol, vol.13, pp.344-358, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01848408

S. C. Hung, K. L. Kuo, C. H. Peng, C. H. Wu, Y. C. Lien et al., Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease, Kidney Int, vol.85, pp.703-709, 2014.

P. Rossignol, Z. A. Massy, M. Azizi, G. Bakris, E. Ritz et al., The double challenge of resistant hypertension and chronic kidney disease, Lancet, vol.386, pp.1588-1598, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01758662

J. J. Mcmurray, S. D. Solomon, S. E. Inzucchi, L. Køber, M. N. Kosiborod et al., Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, N. Engl. J. Med, vol.381, 1995.

V. Perkovic, M. J. Jardine, B. Neal, S. Bompoint, H. J. Heerspink et al., Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy, N. Engl. J. Med, vol.380, pp.2295-2306, 2019.

S. E. Inzucchi, B. Zinman, D. Fitchett, C. Wanner, E. Ferrannini et al., How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial, Diabetes Care, vol.41, pp.356-363, 2018.

J. Januzzi, J. P. Ferreira, M. Böhm, S. Kaul, C. Wanner et al., Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline, Eur. J. Heart Fail, vol.21, pp.386-388, 2019.

N. Girerd, M. F. Seronde, S. Coiro, T. Chouihed, P. Bilbault et al., Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey, JACC Heart Fail, vol.6, pp.273-285, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01847385

P. Rossignol, R. Agarwal, B. Canaud, A. Charney, G. Chatellier et al., Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints, Eur. Heart J, vol.40, pp.880-886, 2019.

S. H. Ramalho, M. Santos, B. Claggett, K. Matsushita, D. W. Kitzman et al., Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study, JAMA Netw

M. G. Shlipak, J. P. Lash, W. Yang, V. Teal, M. Keane et al., Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure, J. Card. Fail, vol.17, pp.17-23, 2011.

W. J. Paulus and C. Tschoepe, A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation, J. Am. Coll. Cardiol, vol.62, pp.263-271, 2013.

H. M. Dubrock, O. F. Abouezzeddine, and M. M. Redfield, High-sensitivity C-reactive protein in heart failure with preserved ejection fraction, PLoS ONE, vol.13, 2018.

A. Kalogeropoulos, V. Georgiopoulou, B. M. Psaty, N. Rodondi, A. L. Smith et al., Inflammatory markers and incident heart failure risk in older adults: The Health ABC (Health, Aging, and Body Composition) study, J. Am. Coll. Cardiol, vol.55, pp.2129-2137, 2010.

S. Sanders-van-wijk, V. Van-empel, N. Davarzani, M. T. Maeder, R. Handschin et al., Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction, Eur. J. Heart Fail, vol.17, pp.1006-1014, 2015.

J. Tromp, B. D. Westenbrink, W. Ouwerkerk, D. J. Van-veldhuisen, N. J. Samani et al., Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction, J. Am. Coll. Cardiol, vol.72, pp.1081-1090, 2018.

B. M. Everett, J. H. Cornel, M. Lainscak, S. D. Anker, A. Abbate et al., Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure, Circulation, vol.139, pp.1289-1299, 2019.

P. Libby, B. L. Ebert, and . Chip, Clonal Hematopoiesis of Indeterminate Potential). Circulation, vol.138, pp.666-668, 2018.

S. Sano, K. Oshima, Y. Wang, S. Maclauchlan, Y. Katanasaka et al., Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1?/NLRP3 Inflammasome, J. Am. Coll. Cardiol, vol.71, pp.875-886, 2018.

W. J. Paulus, Culprit Mechanism(s) for Exercise Intolerance in Heart Failure With Normal Ejection Fraction, J. Am. Coll. Cardiol, vol.56, pp.864-866, 2010.

M. Hieda, S. Sarma, C. M. Hearon, . Jr, K. A. Dias et al., Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure with Preserved Ejection Fraction, Circulation, vol.141, pp.115-123, 2020.

M. N. Peters, S. L. Seliger, R. H. Christenson, S. N. Hong-zohlman, L. B. Daniels et al., Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis), J. Am. Heart Assoc, vol.7, 2018.

K. M. Harris, P. Spirito, M. S. Maron, A. G. Zenovich, F. Formisano et al., Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, vol.114, pp.216-225, 2006.

M. M. Fernandes-silva, A. M. Shah, S. Hegde, A. Goncalves, B. Claggett et al., Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study, JACC Heart Fail, vol.5, pp.157-165, 2017.

M. R. Zile, J. S. Gottdiener, S. J. Hetzel, J. J. Mcmurray, M. Komajda et al., Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction, Circulation, vol.124, pp.2491-2501, 2011.

R. B. Patel, L. A. Colangelo, A. P. Reiner, M. D. Gross, D. R. Jacobs et al., Cellular Adhesion Molecules in Young Adulthood and Cardiac Function in Later Life: The CARDIA Study, J. Am. Coll. Cardiol, vol.2020

F. Tabet, K. C. Vickers, L. F. Torres, C. B. Wiese, B. M. Shoucri et al., HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells, Nat. Commun, vol.5, 2014.

J. G. Bronzwaer and W. J. Paulus, Matrix, cytoskeleton, or myofilaments: Which one to blame for diastolic left ventricular dysfunction?, Prog. Cardiovasc. Dis, vol.47, pp.276-284, 2005.

N. Glezeva, V. Voon, C. Watson, S. Horgan, K. Mcdonald et al., Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: Evidence of M2 macrophage activation in disease pathogenesis, J. Card. Fail, vol.21, pp.167-177, 2015.

M. Kratz, B. R. Coats, K. B. Hisert, D. Hagman, V. Mutskov et al., Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages, Cell Metab, vol.20, pp.614-625, 2014.

J. C. Garbern, J. Williams, A. C. Kristl, A. Malick, I. Rachmin et al., Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis, J. Mol. Cell. Cardiol, vol.128, pp.179-186, 2019.

C. Franssen, S. Chen, A. Unger, H. I. Korkmaz, G. W. De-keulenaer et al., Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure with Preserved Ejection Fraction, JACC Heart Fail, vol.4, pp.312-324, 2016.

R. P. Juni, D. W. Kuster, M. Goebel, M. Helmes, R. J. Musters et al., Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin, JACC Basic Transl. Sci, vol.4, pp.575-591, 2019.

A. Grützner, S. Garcia-manyes, S. Kötter, C. L. Badilla, J. M. Fernandez et al., Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence, Biophys. J, vol.97, pp.825-834, 2009.

Á. Balogh, D. Santer, E. T. Pásztor, A. Tóth, D. Czuriga et al., Myofilament protein carbonylation contributes to the contractile dysfunction in the infarcted LV region of mouse hearts, Cardiovasc. Res, vol.101, pp.108-119, 2014.

G. G. Schiattarella, F. Altamirano, D. Tong, K. M. French, E. Villalobos et al., Nitrosative stress drives heart failure with preserved ejection fraction, Nature, vol.568, pp.351-356, 2019.

M. Fudim, A. P. Ambrosy, J. L. Sun, K. J. Anstrom, B. A. Bart et al., High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients with Heart Failure with Preserved Ejection Fraction: Insights from the Heart Failure Clinical Research Network, J. Am. Heart Assoc, vol.7, 2018.

L. Marshall, K. K. Lee, S. D. Stewart, A. Wild, T. Fujisawa et al., Effect of Exercise Intensity and Duration on Cardiac Troponin Release, Circulation, vol.141, pp.83-85, 2020.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI